TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31274211

Group type: EXPERIMENTAL
Intervention: 7.5 mg vitamin D3
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1 mL normal saline (placebo)
Number of subjects: 90
Study: 28446628

Group type: EXPERIMENTAL
Intervention: Elevated CRP or AGP
Number of subjects: 114

Group type: COMPARATOR
Intervention: Normal CRP and AGP
Number of subjects: 114
Study: 26070652

Group type: EXPERIMENTAL
Intervention: Half-dose L-T4 treatment for 5 weeks (HD group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional L-T4 withdrawal (TW group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Half-dose L-T4 treatment (HD group)
Number of subjects: 55
Study: 25002722

Group type: EXPERIMENTAL
Intervention: Weekly topotecan 4 mg/m² IV with ziv-aflibercept 6 mg/kg IV every 21 days
Number of subjects: 189

Group type: COMPARATOR
Intervention: Weekly topotecan 4 mg/m² IV
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Combined ziv-aflibercept and topotecan
Number of subjects: 189

Group type: COMPARATOR
Intervention: Topotecan alone
Number of subjects: 189
Study: 22332815

Group type: EXPERIMENTAL
Intervention: Preoperative biofeedback (BFB) combined with assisted low-intensity postoperative perineal physiokinesitherapy.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group received only oral and written instructions on Kegel exercises after catheter removal.
Number of subjects: 32
Study: 19295468

Group type: EXPERIMENTAL
Intervention: Diaphragm/gel provision
Number of subjects: 2040

Group type: COMPARATOR
Intervention: Baseline predictors
Number of subjects: 2040
Study: 17713339

Group type: EXPERIMENTAL
Intervention: Individually designed patient-centered preventive program including counseling, toothbrushes, fluoride toothpaste, fluoride and xylitol lozenges, and fluoride/chlorhexidine varnish applications.
Number of subjects: 497

Group type: COMPARATOR
Intervention: Basic prevention offered as standard in public dental clinics.
Number of subjects: 497
Study: 15099605

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benztropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study: 11448848

Group type: EXPERIMENTAL
Intervention: Water immersion (WI) for 3 hours in HF patients
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (seated position)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Water immersion (WI) with sustained angiotensin-converting enzyme inhibitor therapy in HF patients
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control subjects during WI
Number of subjects: 9
Study: 9608577

Group type: EXPERIMENTAL
Intervention: Mecamylamine + Scopolamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Mecamylamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7996097

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Erythromycin base
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Methylprednisolone plus penicillin
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study: 1978478

Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 434

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 434
Study: 375408

Group type: EXPERIMENTAL
Intervention: Levamisole at 3 mg/kg daily for 8 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mebendazole at 6 mg/kg daily for 10 days following 8 days of levamisole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diethylcarbamazine (DEC) at 6 mg/kg daily for 12 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 0
Study: 31992320

Group type: EXPERIMENTAL
Intervention: Low-risk human health and medical research exempt from ethics reviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Existing non-identifiable data and specimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evaluation of public benefit or service programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised controlled trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Research with staff in their professional role
Number of subjects: 0

Group type: COMPARATOR
Intervention: Audit and service evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remaining categories
Number of subjects: 0
Study: 31380891

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: High-bleeding-risk procedure (Apixaban)
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: High-bleeding-risk procedure (Rivaroxaban)
Number of subjects: 3007
Study: 28862466

Group type: EXPERIMENTAL
Intervention: Tooth powder
Number of subjects: 154

Group type: COMPARATOR
Intervention: Toothpaste (Control)
Number of subjects: 154
Study: 25647203

Group type: EXPERIMENTAL
Intervention: 1:1:1 ratio (338 patients)
Number of subjects: 680

Group type: COMPARATOR
Intervention: 1:1:2 ratio (342 patients)
Number of subjects: 680
Study: 23613192

Group type: EXPERIMENTAL
Intervention: Prineo™ (2-octyl cyanoacrylate with self-adhering mesh)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prineo™
Number of subjects: 60
Study: 22036100

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 51
Study: 23120599

Group type: EXPERIMENTAL
Intervention: Endoscopic septoplasty
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional septoplasty
Number of subjects: 50
Study: 17109748

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 176

Group type: COMPARATOR
Intervention: Splinting
Number of subjects: 176
Study: 15011821

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 1522

Group type: EXPERIMENTAL
Intervention: Delayed diagnosis repairs
Number of subjects: 1522

Group type: EXPERIMENTAL
Intervention: Biliary-enteric anastomosis
Number of subjects: 1522
Study: 11176742

Group type: EXPERIMENTAL
Intervention: High-normal BLB group (BLB > or =80 microg and <600 microg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Low BLB group (BLB <80 microg)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Chelation therapy for patients with high-normal BLB
Number of subjects: 110
Study: 9598258

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 40
Study: 7535192

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drugs inhibiting nitric oxide (NO)
Number of subjects: 0
Study: 3377974

Group type: EXPERIMENTAL
Intervention: Monochloroacetic acid crystals and 60% salicylic acid ointment
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 30606082

Group type: EXPERIMENTAL
Intervention: Chewing xylitol-free gum for 30 minutes at 3, 5, and 7 hours postoperatively
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 150
Study: 30998830

Group type: EXPERIMENTAL
Intervention: Recurring presentation of harder or softer pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual prior information (video of indentation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (randomized presentation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit prior information during blocked condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit-only group (no explicit information)
Number of subjects: 0
Study: 28059619

Group type: EXPERIMENTAL
Intervention: Oral rotavirus vaccine (RV) before injection
Number of subjects: 352

Group type: COMPARATOR
Intervention: Oral rotavirus vaccine (RV) after injection
Number of subjects: 352
Study: 26156584

Group type: EXPERIMENTAL
Intervention: DSA negative and DSA MFI <2000 (Group A, n = 316)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: 2000 ≤ MFI < 10,000 (Group B, n = 19)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: MFI ≥ 10,000 (Group C, n = 10)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: DSAs (MFI ≥ 10,000)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: DSAs (MFI ≥ 2000)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Primary graft failure (GF)
Number of subjects: 345
Study: 23392717

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 64
Study: 21730870

Group type: EXPERIMENTAL
Intervention: Endoscopic papillary balloon dilation (EPBD)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 86
Study: 19549749

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 3524

Group type: EXPERIMENTAL
Intervention: Folic acid + iron + zinc
Number of subjects: 3524

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement
Number of subjects: 3524

Group type: COMPARATOR
Intervention: Vitamin A (control)
Number of subjects: 3524
Study: 16819379

Group type: EXPERIMENTAL
Intervention: PEG + E (polyethylene glycol 3350 plus electrolytes)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 63
Study: 15320956

Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: 40 mg citalopram daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram after 8 weeks
Number of subjects: 0
Study: 11055323

Group type: EXPERIMENTAL
Intervention: 3-acetyl-7-oxo-DHEA (50 mg/d for 7 days, 100 mg/d for 7 days, 200 mg/d for 28 days)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 3-acetyl-7-oxo-DHEA (200 mg/d for 28 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9463836

Group type: EXPERIMENTAL
Intervention: 50 mg of sertraline
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 20 mg of paroxetine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (baseline values)
Number of subjects: 7
Study: 8302414

Group type: EXPERIMENTAL
Intervention: CSA liquid (mean dose 312 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CSA capsules (mean dose 312 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CSA liquid
Number of subjects: 20

Group type: COMPARATOR
Intervention: CSA capsules
Number of subjects: 20
Study: 3532669

Group type: EXPERIMENTAL
Intervention: Dietary restriction alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Insulin therapy with dietary advice
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 15
Study: 29734232

Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid (triamcinolone 20 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 28
Study: 27118785

Group type: EXPERIMENTAL
Intervention: Laninamivir octanoate 40 mg single administration (LO‐40SD)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Laninamivir octanoate 20 mg once daily for 2 days (LO‐20TD)
Number of subjects: 803

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study: 24997349

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Resting condition of silent reading
Number of subjects: 31
Study: 22513048

Group type: EXPERIMENTAL
Intervention: ondansetron (8 mg/d; group O, n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: metoclopramide (30 mg/d; group M, n=10)
Number of subjects: 20
Study: 20381932

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (8 sessions, 60 min each over 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 18541546

Group type: EXPERIMENTAL
Intervention: GMP-enriched whey protein isolate (GMP-WPI)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Skim milk powder (SMP)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: GMP-WPI and SMP (both groups)
Number of subjects: 127
Study: 15572587

Group type: COMPARATOR
Intervention: High-dose cytarabine (HiDAC) alone, 3 courses
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Multiagent chemotherapy regimen (1 course of HiDAC, 1 course with etoposide and cyclophosphamide, 1 course with diaziquone and mitoxantrone)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Both regimens (HiDAC and multiagent chemotherapy)
Number of subjects: 474
Study: 12867227

Group type: EXPERIMENTAL
Intervention: Loop recorder for 1 month
Number of subjects: 100

Group type: COMPARATOR
Intervention: Holter monitor for 48 hours
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Loop recorder after negative Holter monitoring
Number of subjects: 100

Group type: COMPARATOR
Intervention: Holter monitor after negative loop recorder
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Loop recorders overall
Number of subjects: 100

Group type: COMPARATOR
Intervention: Holter monitors overall
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Loop recorder activation
Number of subjects: 100
Study: 10537442

Group type: EXPERIMENTAL
Intervention: Addition of lamivudine to zidovudine-containing regimens for 1 year
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: Addition of lamivudine to zidovudine-containing regimens
Number of subjects: 1840
Study: 8867494

Group type: EXPERIMENTAL
Intervention: HRCT
Number of subjects: 30
Study: 2072075

Group type: EXPERIMENTAL
Intervention: Experimental departments (prevention programme)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control departments
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Experimental departments (women)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Experimental departments (men)
Number of subjects: 412
Study: 6439036

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31301034

Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Resistance Training (BFR‐RT) at 30% 1RM
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional Heavy Load Resistance Training (HL‐RT) at 70% 1RM
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Resistance Training (BFR‐RT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional Heavy Load Resistance Training (HL‐RT)
Number of subjects: 24
Study: 29032859

Group type: EXPERIMENTAL
Intervention: High-DHA tuna oil (800mg/day DHA)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 252
Study: 26829088

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation during weight-bearing exercises
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (selected program without neuromuscular electrical stimulation)
Number of subjects: 42
Study: 24850433

Group type: EXPERIMENTAL
Intervention: Diluted chlorhexidine gluconate (0.4% to 100%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Two scrubs of 50% diluted CHG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: One scrub of 50% diluted CHG
Number of subjects: 60
Study: 22920577

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment (intramuscularly)
Number of subjects: 75
Study: 21060024

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy followed by surgery
Number of subjects: 144

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study: 17637792

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (matched hypertensive subjects without LV hypertrophy)
Number of subjects: 129
Study: 16182827

Group type: EXPERIMENTAL
Intervention: Tacrolimus (initial oral dose 0.2 mg/kg) with MMF (2 to 3 g per day) and rATG induction therapy (4 mg/kg for 4 days)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Cyclosporine‐microemulsion (ME) (initial daily oral dose 7 mg/kg) with MMF (2 to 3 g per day) and rATG induction therapy (1.25 mg/kg for 4 days)
Number of subjects: 103
Study: 12559940

Group type: EXPERIMENTAL
Intervention: Inogatran (a direct thrombin inhibitor)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: High fibrinogen level (pre-treatment top tertile)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: High C-reactive protein level
Number of subjects: 320
Study: 10379283

Group type: EXPERIMENTAL
Intervention: Provisional resin crowns (n = 25)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healing abutments (n = 38)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 8919900

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TS)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 263
Study: 1832982

Group type: EXPERIMENTAL
Intervention: alpha‐human ANF (hANF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: vehicle alone
Number of subjects: 20
Study: 7166045

Group type: EXPERIMENTAL
Intervention: Right hand stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Left hand stimulation
Number of subjects: 0
Study: 31182135

Group type: EXPERIMENTAL
Intervention: High mean arterial blood pressure target (77 mm Hg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low mean arterial blood pressure target (63 mm Hg)
Number of subjects: 60
Study: 29255272

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg every other day, once a morning
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard arm (control)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 88
Study: 25475774

Group type: EXPERIMENTAL
Intervention: Verbal presentation of postoperative instructions
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Written presentation of postoperative instructions
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Presentation of postoperative instructions with additional information
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Preoperative anxiety scores
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sociocultural level
Number of subjects: 84
Study: 23701115

Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation (SV) using dexmedetomidine (4 μg∙kg(‐1)) and topical lidocaine (3‐5 mg∙kg(‐1))
Number of subjects: 80

Group type: COMPARATOR
Intervention: Manual jet ventilation (MJV) with fentanyl (2 μg∙kg(‐1)), propofol (3‐5 mg∙kg(‐1)), and succinylcholine (1 mg∙kg(‐1))
Number of subjects: 80
Study: 21153657

Group type: EXPERIMENTAL
Intervention: Men (n = 31)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Women (n = 32)
Number of subjects: 63
Study: 19214115

Group type: EXPERIMENTAL
Intervention: Diaphragm + gel + condoms
Number of subjects: 2429
Study: 16749408

Group type: EXPERIMENTAL
Intervention: EOS strategy (sputum eosinophils reduction)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard strategy (based on symptoms and lung function)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: EOS strategy
Number of subjects: 55
Study: 15328781

Group type: COMPARATOR
Intervention: Yaw rotation and brief head roll to 35 +/- 2 degrees
Number of subjects: 16
Study: 11436970

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy plus immunotherapy (IT) in tablets
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pharmacotherapy alone (Control)
Number of subjects: 51
Study: 9132703

Group type: EXPERIMENTAL
Intervention: Jokes condition (computer presented jokes first)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Problems condition (computer presented problems first)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Computer-anxious group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Computer-nonanxious group
Number of subjects: 40
Study: 8290411

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg) + Amiloride (2.5 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg) + Triamterene (50 mg)
Number of subjects: 41
Study: 3708884

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Submucosal diathermy
Number of subjects: 0
Study: 30550209

Group type: EXPERIMENTAL
Intervention: Combined treatment with nasal corticosteroids (budesonide) and nasal antihistamine (azelastine) for 8 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Budesonide alone for 8 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Azelastine alone for 8 weeks
Number of subjects: 120
Study: 27138024

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) 400/12 μg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aclidinium bromide 400 μg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Formoterol fumarate 12 μg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide/formoterol fumarate FDC
Number of subjects: 30
Study: 25137221

Group type: EXPERIMENTAL
Intervention: 30 min/day walking prescription
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 60 min/day walking prescription
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 90 min/day walking prescription
Number of subjects: 55
Study: 22568858

Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision procedure (LEEP)
Number of subjects: 338

Group type: COMPARATOR
Intervention: CO2 laser vaporization
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Both LEEP and CO2 laser vaporization
Number of subjects: 338
Study: 20524104

Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 18212331

Group type: EXPERIMENTAL
Intervention: Directional goal to discredit a threatening message
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonthreatening message
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accuracy goal introduced
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Removing directional goal or adding accuracy goal
Number of subjects: 0